ADD CONDITION
Narasin
Last content change checked dailysee data sync status
- Active ingredient
- Narasin 100 g/1 kg
- Reference brand
- Skycis
- Dosage form
- Granule
- Route
- Oral
- Prescription status
- Animal
- Marketed in the U.S.
- Since 2012
- Label revision date
- January 21, 2026
- Pregnancy
- See Pregnancy Use Section
- Lactation
- See Lactation Use Section
- Active ingredient
- Narasin 100 g/1 kg
- Reference brand
- Skycis
- Dosage form
- Granule
- Route
- Oral
- Prescription status
- Animal
- CSA schedule
- Not a scheduled drug
- Marketed in the U.S.
- Since 2012
- Label revision date
- January 21, 2026
- Pregnancy
- See Pregnancy Use Section
- Lactation
- See Lactation Use Section
If you are a healthcare professional or from the pharmaceutical industry please visit this version.
If you are a consumer or patient please visit this version.
Drug Overview
Skycis and Monteban are both types of medicated articles containing narasin, specifically designed for use in swine feeds. Narasin is an active ingredient that helps promote an increased rate of weight gain in growing-finishing swine when fed continuously for at least four weeks. These products are formulated as granules and are intended to be mixed into the feed for swine, ensuring that the appropriate concentration of narasin is maintained for optimal effectiveness.
It is important to note that these products are not approved for use in breeding animals or for human consumption. Additionally, swine receiving these medications should not have access to feeds containing certain other medications, as this could lead to adverse reactions. Always consult with a veterinarian or animal health professional for guidance on proper use.
Uses
You can use Skycis granules to help growing-finishing swine gain weight more effectively. When fed continuously for at least four weeks, this product can increase the rate of weight gain and improve feed efficiency in these animals. It's important to provide it as the sole ration during this period to achieve the best results. Please note that the effectiveness of Skycis has not been shown for feeding durations shorter than four weeks.
Dosage and Administration
To use Skycis granules for improving weight gain in growing-finishing swine, you should mix the granules with non-medicated swine feed. The recommended dosage is between 13.6 to 27.2 grams per ton (15 to 30 parts per million) of feed. For optimal results, feed this mixture continuously for at least four weeks, as effectiveness has not been shown for shorter durations.
When preparing the feed, follow these mixing directions: For Type B Medicated Feed, use 55.12 pounds of Skycis to achieve 2,500 grams per ton (1.25 ppm) or 110.23 pounds for 5,000 grams per ton (2.50 ppm). For Type C Medicated Feed, you can mix 0.3 pounds for 13.6 grams per ton (15 ppm), 0.4 pounds for 18.1 grams per ton (20 ppm), or 0.6 pounds for 27.2 grams per ton (30 ppm). Make sure to administer the feed orally as the sole ration during the growing-finishing period.
What to Avoid
You should avoid using Skycis (narasin) if you have access to adult turkeys, horses, or other equines, as ingestion can be fatal. It is not approved for breeding animals due to untested safety and effectiveness. Additionally, swine fed with Skycis should not have access to feeds containing pleuromutilins (like tiamulin) to prevent adverse reactions. Remember, this medication is classified as a restricted drug in California and is strictly for veterinary use—do not use it for humans.
Side Effects
When using Skycis or Monteban granules, it's important to take precautions during mixing and handling. You should wear protective clothing, impervious gloves, and a dust mask to avoid exposure. If you accidentally get the granules in your eyes, rinse them thoroughly with water.
There is no withdrawal period required for Skycis when used as directed. For any technical assistance or to report side effects, you can contact Elanco US Inc. at 1-800-428-4441 or the FDA at 1-888-FDA-VETS for animal drug side effects.
Warnings and Precautions
When using Skycis or Monteban, it's important to take safety precautions. Always wear protective clothing, impervious gloves, and a dust mask while mixing and handling these granules. After handling, wash your hands thoroughly with soap and water. If the product accidentally gets into your eyes, rinse them immediately with water.
Both products are classified as restricted drugs in California, meaning you should use them only as directed. If you experience any adverse effects or need more information, you can call 1-800-428-4441 for assistance. There are no specific instructions to stop taking these medications or to call your doctor, but always consult your healthcare provider if you have concerns.
Overdose
If you take too much of Skycis or Monteban 45 granules, there is no specific information available about what to expect or how to respond. However, if you suspect an overdose, it's important to monitor yourself for any unusual symptoms. Signs of an overdose can vary, but if you experience anything concerning, such as extreme drowsiness or difficulty breathing, seek medical help immediately. Always contact your healthcare provider or local poison control center for guidance in case of an overdose.
Pregnancy Use
When considering the use of Skycis during pregnancy, it's important to note that this medication has not been evaluated for safety and effectiveness in breeding animals. While there are no specific warnings regarding its use in pregnant individuals, the lack of data means that you should consult your healthcare provider before using it. Always prioritize your health and the health of your baby by discussing any medications you are considering.
Lactation Use
When breastfeeding, it's important to be aware that there is no specific information available regarding the use of Skycis for nursing mothers. This means that the effects on lactation, the potential for the medication to pass into breast milk, and any associated risks for your infant have not been studied or documented. If you have concerns about medications while breastfeeding, it's always best to consult with your healthcare provider for personalized advice.
Pediatric Use
There is no specific information regarding the use of Skycis (narasin) in children. The available data primarily focuses on its application in swine feeds, and it does not provide any recommendations for age limits, dosage differences, safety concerns, or special precautions for pediatric use. Therefore, if you are considering this medication for a child, it is important to consult a healthcare professional for guidance.
Geriatric Use
When considering Skycis granules for older adults, it's important to note that there is no specific information available regarding dosage adjustments, safety concerns, or special precautions for elderly patients. This means that while the medication may be used, you should consult with your healthcare provider to ensure it is appropriate for your individual health needs, especially if you have other medical conditions or are taking multiple medications. Always prioritize open communication with your doctor about any concerns or questions you may have regarding your treatment.
Renal Impairment
When it comes to medications like Skycis and Monteban 45, there is currently no specific information available regarding how they should be adjusted or monitored for individuals with kidney problems. This means that if you have renal impairment, it's important to consult your healthcare provider for personalized advice, as they can help determine the best course of action based on your individual health needs. Always prioritize open communication with your doctor about any kidney issues you may have when considering these medications.
Hepatic Impairment
You may be wondering about the effects of liver issues on certain medications. For both Skycis and Monteban 45, there is no specific information available regarding how liver impairment (a condition where the liver does not function properly) affects the use of these medications. This means there are no recommended dosage adjustments or special monitoring guidelines for patients with liver problems provided in the product information.
If you have liver concerns, it's always best to consult your healthcare provider for personalized advice before starting any new medication.
Drug Interactions
When using Skycis (narasin) in swine, it's important to ensure that they do not have access to feeds containing pleuromutilins, such as tiamulin, as this can lead to adverse reactions. If you notice any signs of toxicity, you should stop using the product immediately.
Always discuss any medications or treatments with your veterinarian to ensure the safety and health of your animals. This is crucial because certain combinations can lead to unexpected side effects or reduced effectiveness of treatments.
Storage and Handling
To ensure the best quality and safety of Skycis granules, store the product at or below 25°C (77°F), with brief excursions allowed up to 37°C (99°F). Always check the expiration date printed on the bag before use.
When mixing or handling Skycis, it’s important to wear protective clothing, impervious gloves, and a dust mask to prevent exposure. After handling, wash your hands thoroughly with soap and water. In case of accidental eye contact, rinse your eyes immediately with water.
FAQ
What is Skycis™ 100?
Skycis™ 100 is a Narasin Type A medicated article specifically designed for use in swine feeds.
What is the primary use of Skycis™ 100?
It is indicated for increasing the rate of weight gain in growing-finishing swine when fed for at least four weeks.
What is the recommended dosage for Skycis™ 100?
For increased weight gain, feed 13.6 to 27.2 g/ton (15 ppm to 30 ppm) for at least four weeks.
How should Skycis™ 100 be administered?
Skycis™ 100 should be mixed thoroughly with non-medicated swine feed and fed continuously as the sole ration for at least four weeks.
Are there any precautions when using Skycis™ 100?
Yes, do not allow adult turkeys, horses, or other equines access to narasin formulations, as ingestion can be fatal.
Is Skycis™ 100 safe for breeding animals?
No, it is not approved for use in breeding animals because safety and effectiveness have not been evaluated in these animals.
What should I do if I notice signs of toxicity in swine fed with Skycis™ 100?
If signs of toxicity occur, discontinue use immediately.
Is there a withdrawal period for Skycis™ 100?
No withdrawal period is required when used according to the label.
What should I wear when handling Skycis™ 100?
When mixing and handling Skycis™, use protective clothing, impervious gloves, and a dust mask.
Is Skycis™ 100 approved for human use?
No, Skycis™ 100 is not for human use.
What is Monteban™ 45?
Monteban™ 45 is a narasin Type A medicated article manufactured by Elanco™, with a net weight of 25 kg (55.12 lb).
How should Monteban 45 be mixed for Type C feeds?
For Type C feeds, mix Monteban 45 in amounts ranging from 54 g to 90 g per ton of feed, with a preblend in 15 - 20 lbs of feed before incorporation.
What is the recommended administration method for Type C medicated feed?
Administer the resulting Type C medicated feed continuously as the sole ration.
What precautions should I take when handling Monteban?
When mixing and handling Monteban, use protective clothing, impervious gloves, and a dust mask. Wash thoroughly with soap and water after handling.
What should I do if I accidentally get Monteban in my eyes?
If accidental eye contact occurs, immediately rinse thoroughly with water.
Is Monteban safe for all animals?
No, do not allow adult turkeys, horses, or other equines access to narasin formulations, as ingestion can be fatal.
What is the storage requirement for Monteban?
Store Monteban at or below 25° C (77° F), with excursions permitted to 37° C (99° F).
Is Monteban intended for human use?
No, Monteban is not for human use.
What should I do in case of an emergency related to Monteban?
To report adverse effects or obtain additional product information, call 1-800-428-4441.
Uses and Indications
This drug is indicated for increased rate of weight gain in growing-finishing swine when fed for at least four weeks. It is also indicated for improved feed efficiency in growing-finishing swine under the same feeding regimen.
Usage Instructions: The drug should be fed continuously as the sole ration to swine during the growing-finishing period for a minimum duration of four weeks. Effectiveness has not been demonstrated when fed for periods shorter than four weeks.
Limitations of use for the second label, Monteban 45, are not specified in the provided information.
Dosage and Administration
For the increased rate of weight gain in growing-finishing swine, Skycis should be administered at a dosage of 13.6 to 27.2 g/ton (15 ppm to 30 ppm) when fed for a minimum duration of four weeks. For both increased rate of weight gain and improved feed efficiency, a dosage of 18.1 to 27.2 g/ton (20 ppm to 30 ppm) is recommended, also for at least four weeks. It is important to note that the effectiveness of Skycis has not been demonstrated when fed for durations shorter than four weeks.
Skycis should be fed continuously as the sole ration to swine during the growing-finishing period. The route of administration is oral. To achieve the proper concentration in Type B and Type C Medicated Feed, Skycis 100 Type A Medicated Article must be thoroughly mixed with non-medicated swine feed according to the following mixing directions:
For Type B Medicated Feed:
Mixing 55.12 lbs of Skycis results in a concentration of 2,500 g/ton (1.25 ppm).
Mixing 110.23 lbs results in a concentration of 5,000 g/ton (2.50 ppm).
For Type C Medicated Feed:
Mixing 0.3 lb results in a concentration of 13.6 g/ton (15 ppm).
Mixing 0.4 lb results in a concentration of 18.1 g/ton (20 ppm).
Mixing 0.6 lb results in a concentration of 27.2 g/ton (30 ppm).
Healthcare professionals should ensure that the mixing is performed accurately to maintain the intended dosage and effectiveness of the medication.
Contraindications
Do not allow adult turkeys, horses, or other equines access to narasin formulations, as ingestion of narasin by these species has been fatal. Skycis is not approved for use in breeding animals due to the lack of evaluated safety and effectiveness in these populations. Swine being fed with Skycis (narasin) should not have access to feeds containing pleuromutilins, such as tiamulin, as adverse reactions may occur. Additionally, this product is not for human use.
Warnings and Precautions
When mixing and handling Skycis and Monteban, it is essential to use protective clothing, impervious gloves, and a dust mask. Operators must wash thoroughly with soap and water after handling. In the event of accidental eye contact, it is crucial to rinse the eyes thoroughly with water immediately.
Serious Warnings
No withdrawal period is required when using Skycis according to the label. Both Skycis and Monteban are classified as restricted drugs in California and should be used only as directed.
General Precautions
Operators should adhere to safety measures while handling these products to prevent exposure and potential adverse effects.
Monitoring Requirements
No specific laboratory tests are mentioned for either Skycis or Monteban.
Emergency Information
For Monteban, to report adverse effects, access medical information, or obtain additional product information, individuals should call 1-800-428-4441. No specific instructions are provided for seeking emergency medical help or for stopping the medication and contacting a doctor for either product.
Side Effects
Patients using Skycis and Monteban 45 may experience various adverse reactions associated with the handling and administration of these medications.
Warnings
Both Skycis and Monteban 45 require the use of protective clothing, impervious gloves, and a dust mask during mixing and handling. Operators are advised to wash thoroughly with soap and water after handling. In the event of accidental eye contact, it is crucial to rinse the eyes thoroughly with water.
Reporting Adverse Reactions
For technical assistance or to report side effects related to Skycis, patients or caregivers should contact Elanco US Inc. at 1-800-428-4441. For additional information regarding the reporting of side effects for animal drugs, individuals can reach out to the FDA at 1-888-FDA-VETS or visit FDA's reporting pageFDA's reporting page.
Drug Interactions
Swine administered Skycis (narasin) should not be given access to feeds containing pleuromutilins, such as tiamulin, due to the potential for adverse reactions. In the event that signs of toxicity are observed, it is recommended to discontinue the use of Skycis. No additional information regarding drug interactions or interactions with laboratory tests has been provided.
Pediatric Use
There is no specific pediatric use information available for Skycis (narasin). The insert primarily addresses its application in swine feeds and does not provide any recommendations regarding age ranges, dosing differences, safety concerns, or special precautions for pediatric patients.
Geriatric Use
Elderly patients may not have specific dosage adjustments or safety concerns outlined for Skycis. However, as with any medication, it is advisable for healthcare providers to monitor geriatric patients closely for any adverse effects or changes in efficacy, given the potential for altered pharmacokinetics in this population.
Pregnancy
Pregnant patients should be aware that Skycis has not been approved for use in breeding animals, as safety and effectiveness have not been evaluated in these populations. Therefore, the potential risks and fetal impacts associated with the use of Skycis during pregnancy remain undetermined. Healthcare professionals are advised to exercise caution and consider alternative treatments when managing conditions in pregnant patients. It is recommended that pregnant patients discuss any medication use with their healthcare provider to ensure the safety of both the patient and the fetus.
Lactation
There is no specific information available regarding the use of Skycis in lactating mothers. Additionally, there are no data on the potential for excretion in breast milk or any associated risks for breastfed infants. Healthcare professionals should exercise caution and consider the lack of lactation-specific data when advising lactating patients.
Renal Impairment
Patients with renal impairment have not been specifically addressed in the available labeling for Skycis and Monteban 45. There are no dosage adjustments, special monitoring requirements, or safety considerations provided for individuals with reduced kidney function in the respective product information. Therefore, healthcare professionals should exercise caution and consider individual patient circumstances when prescribing these medications to patients with renal impairment, as the lack of specific guidance necessitates careful clinical judgment.
Hepatic Impairment
Patients with hepatic impairment have not been specifically addressed in the available data for Skycis and Monteban 45. There are no dosage adjustments, special monitoring requirements, or precautions outlined for this patient population in the respective product inserts. Therefore, healthcare professionals should exercise caution and consider individual patient factors when prescribing these medications to patients with liver problems.
Overdosage
In the event of an overdose, specific information regarding the management and symptoms associated with the overdosage of Skycis and Monteban 45 is not provided in the available literature. Therefore, it is recommended that healthcare professionals monitor patients closely for any unusual symptoms or adverse effects that may arise following excessive intake of these medications.
In the absence of detailed overdosage information, standard supportive care should be initiated. This may include monitoring vital signs, providing symptomatic treatment, and ensuring the patient’s safety. If an overdose is suspected, it is advisable to contact a poison control center or seek immediate medical attention for further guidance on management strategies.
Nonclinical Toxicology
Teratogenicity
No teratogenic effects have been reported in studies involving Skycis.
Impairment of Fertility
Skycis is not approved for use in breeding animals, as the safety and effectiveness of the product have not been evaluated in these populations.
Animal Toxicology
Swine administered Skycis (narasin) should be kept away from feeds containing pleuromutilins, such as tiamulin, due to the potential for adverse reactions. In cases where signs of toxicity are observed, it is recommended to discontinue use immediately. Additionally, the ingestion of narasin by adult turkeys, horses, or other equines has resulted in fatal outcomes.
Storage and Handling
Skycis is supplied in granule form. It should be stored at or below 25°C (77°F), with excursions permitted up to 37°C (99°F). The product must not be used after the date printed on the bag.
When mixing and handling Skycis, it is essential to use protective clothing, impervious gloves, and a dust mask to ensure safety. Operators are advised to wash thoroughly with soap and water after handling the product. In the event of accidental eye contact, it is crucial to rinse the eyes thoroughly with water immediately.
Product Labels
The table below lists all veterinary labels containing narasin. Use it to compare formulations, strengths, and approved species across products.
More Details | |||||
|---|---|---|---|---|---|
Elanco US Inc. | Granule | Oral | 100 g/1 kg | 2012 | |
Indications
| |||||
Elanco US Inc. | Granule | Oral | 100 g/1 kg | 2012 | |
Indications
| |||||